The latest price target for Revelation Biosciences (NASDAQ:REVB) was reported by Roth MKM on February 14, 2023. The analyst firm set a price target for $15.00 expecting REVB to rise to within 12 months (a possible 685.34% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Revelation Biosciences (NASDAQ:REVB) was provided by Roth MKM, and Revelation Biosciences maintained their buy rating.

There is no last upgrade for Revelation Biosciences

There is no last downgrade for Revelation Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revelation Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revelation Biosciences was filed on February 14, 2023 so you should expect the next rating to be made available sometime around February 14, 2024.

While ratings are subjective and will change, the latest Revelation Biosciences (REVB) rating was a maintained with a price target of $5.00 to $15.00. The current price Revelation Biosciences (REVB) is trading at is $1.91, which is out of the analyst’s predicted range.